The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WORLD TECHNOLOGY NETWORK AWARD

31 Oct 2011 07:00

RNS Number : 1066R
Angle PLC
31 October 2011
 



 

 

For immediate release

31 October 2011

 

ANGLE plc ("the Company")

 

WORLD TECHNOLOGY NETWORK AWARD

 

 

ANGLE plc ("ANGLE"), which focuses on the commercialisation of technology, is delighted to announce that its Middle East Director, Dr Athar Osama has been awarded the prestigious World Technology Network (WTN) award and has been elected as a fellow of the WTN.

 

ANGLE employee, Dr Osama is the first Pakistani to receive the WTN award, which are seen as the "Oscars of Science and Technology". With this award, WTN has recognised www.Muslim-Science.com, which was founded by Dr Osama as an agent of change.

 

Muslim-Science.com is designed as a platform for a dialogue among Muslims and between Muslims and other communities about the state of science and technology in the Muslim World and the influence of Muslim faith on the former.

 

The Previous WTN award winners include Al Gore (US former Vice President), Mohammad Yunus (founder of Grameen Bank), Mark Zuckurberg (Facebook founder), Larry Page (Google) and Tim Berners-Lee (Inventor of Internet).

 

Dr Athar Osama, Director of Middle East and Asia for ANGLE commented: 

"I am honoured to have received this award. There is major potential in connecting Muslim technology to Western markets and vice versa. The Muslim World that has for too long now been only a consumer of knowledge and technology generated in the West now has an opportunity to leapfrog several stages of development and become both an intelligent user and producer of scientific knowledge and technological innovation. Many Islamic countries, including Saudi Arabia, Qatar, UAE, Malaysia, Pakistan, Iran, Jordan, and Egypt have, in recent years, shown remarkable ambition to invest heavily in science and innovation and ANGLE is pleased to have played our part in laying the foundation of a science and innovation revolution in the Islamic World."

 

Andrew Newland, Chief Executive of ANGLE commented: 

"We are very proud of Athar's success. Dialogue about science and technology is an excellent way to improve understanding between the Muslim and non-Muslim communities and ANGLE is delighted to have supported this communication through our extensive involvement in the Middle East over the last several years."

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8350

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAEEEDFLFFAF
Date   Source Headline
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.